Publicaciones Recientes – Alma Delia Campos Parra

2025

Persistent Cervical Infection with the Chikungunya Virus. Pérez-Pérez, José Eduardo, Guzmán-Martínez, Oscar, Torres-Flores, Jesús Miguel, Sampieri, Clara Luz, Pérez-Carreón, Julio Isael, López-Balderas, Nayali, Barragán, Miguel Ángel, Mendoza-Cervantes, Guillermo, García-García, Fabio, Campos, Alma, Sánchez-Marín, David, Montero, Hilda. Revista da Sociedade Brasileira de Medicina Tropical. 2025. 10.1590/0037-8682-0304-2024 .

Editorial: Repurposed drugs targeting cancer signaling pathways: clinical insights to improve oncologic therapies, volume II. Campos-Parra, Alma D, Leyva-Gomez, Gerardo, Padilla-Benavides, Teresita. Frontiers Media SA. 2025. 10.3389/fonc.2025.1628842

MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships. Campos-Parra, Alma D, Sánchez-Marín, David,Acevedo-Sánchez, Víctor. Multidisciplinary Digital Publishing Institute (MDPI). 2025. 10.3390/ph18040492

2024

Breaking paradigms: Long non-coding RNAs forming gene fusions with potential implications in cancer. Sánchez-Marín D, Silva-Cázares MB, Porras-Reyes FI, García-Román R, Campos-Parra AD. Genes Dis. 2023 Oct 11;11(3):101136. doi: 10.1016/j.gendis.2023.101136. eCollection 2024 May. PMID: 38292185

Drug repositioning in thyroid cancer: from point mutations to gene fusions.Sánchez-Marín D, Silva-Cázares MB, González-Del Carmen M, Campos-Parra AD. Front Oncol. 2024 May 8;14:1407511. doi: 10.3389/fonc.2024.1407511. eCollection 2024. PMID: 38779099

2023

Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis. Jordan-Alejandre E, Campos-Parra AD, Castro-López DL, Silva-Cázares MB. Cells. 2023 Feb 6;12(4):525. doi: 10.3390/cells12040525. PMID: 36831192

Pathogenic variant profile in DNA damage response genes correlates with metastatic breast cancer progression-free survival in a Mexican-mestizo population. Vázquez-Romo R, Millan-Catalan O, Ruíz-García E, Martínez-Gutiérrez AD, Alvarado-Miranda A, Campos-Parra AD, López-Camarillo C, Jacobo-Herrera N, López-Urrutia E, Guardado-Estrada M, Cantú de León D, Pérez-Plasencia C. Front Oncol. 2023 Apr 27;13:1146008. doi: 10.3389/fonc.2023.1146008. eCollection 2023. PMID: 37182128

2022

Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers. Campos-Parra AD, Pérez-Quintanilla M, Martínez-Gutierrez AD, Pérez-Montiel D, Coronel-Martínez J, Millan-Catalan O, De León DC, Pérez-Plasencia C. Curr Oncol. 2022 Jul 5;29(7):4689-4702. doi: 10.3390/curroncol29070372. PMID: 35877232

LncRNAs driving feedback loops to boost drug resistance: sinuous pathways in cancer. Sánchez-Marín D, Trujano-Camacho S, Pérez-Plasencia C, De León DC, Campos-Parra AD. Cancer Lett. 2022 Sep 1;543:215763. doi: 10.1016/j.canlet.2022.215763. Epub 2022 Jun 7. PMID: 35680071

Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer. Contreras-Romero C, Pérez-Yépez EA, Martinez-Gutierrez AD, Campos-Parra A, Zentella-Dehesa A, Jacobo-Herrera N, López-Camarillo C, Corredor-Alonso G, Martínez-Coronel J, Rodríguez-Dorantes M, de León DC, Pérez-Plasencia C. Front Oncol. 2022 Mar 3;12:773438. doi: 10.3389/fonc.2022.773438. eCollection 2022. PMID: 35359376